Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CFO Steven Cook sold 23,263 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $22.76, for a total transaction of $529,465.88. Following the completion of the sale, the chief financial officer owned 187,209 shares of the company’s stock, valued at approximately $4,260,876.84. This represents a 11.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Omada Health Price Performance
Shares of OMDA opened at $22.98 on Thursday. The company has a market cap of $1.37 billion and a PE ratio of -85.11. The firm has a 50-day moving average of $17.83 and a 200-day moving average of $15.27. Omada Health, Inc. has a one year low of $10.28 and a one year high of $26.92.
Omada Health (NASDAQ:OMDA – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The company had revenue of $78.05 million for the quarter. Analysts expect that Omada Health, Inc. will post -0.01 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the company. Wall Street Zen upgraded Omada Health from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. JPMorgan Chase & Co. dropped their price objective on shares of Omada Health from $32.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, March 12th. Weiss Ratings raised shares of Omada Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. Morgan Stanley restated an “overweight” rating and set a $30.00 target price on shares of Omada Health in a research report on Monday, June 22nd. Finally, Citizens Jmp lifted their price target on shares of Omada Health from $18.00 to $21.00 and gave the company a “market outperform” rating in a research report on Friday, May 8th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.91.
Get Our Latest Stock Report on Omada Health
About Omada Health
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Further Reading
- Five stocks we like better than Omada Health
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
